$Emerging role of multikinase inhibitors for refractory thyroid cancer$
QR Code

QR Code

Emerging role of multikinase inhibitors for refractory thyroid cancer

Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Perez CA, Arango BA, Velez M, Raez LE, Santos ES
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2012
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/3179f4c79c1e45caa8c0a2a829772923
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
par: Stjepanovic N, et autres
Publié: (2014)

Multikinase inhibitors use in differentiated thyroid carcinoma
par: Jasim S, et autres
Publié: (2014)

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
par: Ke Y, et autres
Publié: (2018)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
par: Anne Christine Kaae, et autres
Publié: (2021)

Role of vandetanib in the management of medullary thyroid cancer
par: Rondeau G, et autres
Publié: (2012)

Evolutionary history expands the range of signaling interactions in hybrid multikinase networks
par: Philippe Ortet, et autres
Publié: (2021)

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
par: Sabina Luszczak, et autres
Publié: (2020)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
par: Mary F Mulcahy
Publié: (2008)

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
par: Maciej Ratajczak, et autres
Publié: (2021)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
par: Shannon Puhalla, et autres
Publié: (2008)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
par: William Boland, et autres
Publié: (2010)

The role of the size in thyroid cancer risk stratification
par: Federica Vianello, et autres
Publié: (2021)

SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
par: Murugan AK, et autres
Publié: (2021)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
par: Bernadette Biondi, et autres
Publié: (2008)

Management of bone metastases in refractory prostate cancer – role of denosumab
par: Paller CJ, et autres
Publié: (2012)

Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema
par: Al Kahtani ES
Publié: (2015)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
par: Liu L, et autres
Publié: (2017)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
par: Radhakrishnan Ramchandren, et autres
Publié: (2009)

Selenium and thyroid autoimmunity
par: Roberto Negro
Publié: (2008)

Emerging nanotechnology approaches in tissue engineering and regenerative medicine
par: Kim ES, et autres
Publié: (2014)

Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer
par: Sorina Martin, et autres
Publié: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
par: Giacomo Barchiesi, et autres
Publié: (2021)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
par: Shansa Pranami E. Jayaweera, et autres
Publié: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
par: Nooka A, et autres
Publié: (2013)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
par: Nguyen KS, et autres
Publié: (2012)

Screening Leads to Overestimated Associations of Thyroid Dysfunction and Thyroiditis with Thyroid Cancer Risk
par: Young Shin Song, et autres
Publié: (2021)

Treatment of refractory complex partial seizures: role of vigabatrin
par: Elizabeth J Waterhouse, et autres
Publié: (2009)

Etiology of 305 cases of refractory hematospermia and therapeutic options by emerging endoscopic technology
par: Liang-Gong Liao, et autres
Publié: (2019)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
par: Marco Montillo, et autres
Publié: (2008)

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
par: Salehzadeh F, et autres
Publié: (2019)

Associated Factors in Response to Treatment in Children with Refractory Epilepsy
par: MM Nasehi, et autres
Publié: (2010)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
par: Sachin Gupta, et autres
Publié: (2008)

Ovarian cancer: emerging molecular-targeted therapies
par: Sourbier C
Publié: (2012)

Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour
par: Seung-hwan Jeong, et autres
Publié: (2021)

Differentiated thyroid cancer
par: Dmitrii G. Bel’tsevich, et autres
Publié: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
par: Pan Shen, et autres
Publié: (2021)

Predictors of Malignancy in Thyroid Nodules
par: Abdel Rahman Ahmed Mohamed Ragab, et autres
Publié: (2021)

TIRADS effectiveness in cancer risk prognosis among patients with cystic and solid thyroid nodules
par: V.N. Marina, et autres
Publié: (2018)

The role of thyroid stimulating hormone in the timing of thyroxin supplement after thyroid operations
par: Basil Abdulrazzaq Saadallah Al-Khayyat
Publié: (2021)

Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles
par: Hu Z, et autres
Publié: (2019)